The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR
Open accessAbstract
Triple negative breast cancer (TNBC) patients are not likely to benefit from anti-estrogen or anti-HER2 therapy and this phenotype is associated with a more aggressive clinical course and worse clinical outcome. Taking into account the limited treatment possibilities in TNBC, the aim of the present work was to study a potential therapy based on Cetuximab-mediated immune activity by natural killer (NK) cells. We performed in vitro studies on human breast cancer (BC) cell lines, IIB-BR-G, and the in vivo metastatic variant IIB-BR-G MT. The immunohistochemical analysis showed a TNBC phenotype with high but different levels of EGFR expression on each cell line, measured by flow cytometry. DNA sequencing showed that both cell lines have a mutated K-RAS status, 38 G > A at codon 13. Consequently, Cetuximab did not inhibit cellular proliferation or induce apoptosis. We investigated if Cetuximab could trigger immune mechanisms, and we determined that both cell lines treated with 1 μg/ml Cetuximab were susceptible to antibody dependent cellular cytotoxicity (ADCC), mediated by peripheral blood mononuclear cells (PBMC). At 50:1 effector:target ratio, lytic activity was 34 ± 2% against IIB-BR-G and 27 ± 6% against IIB-BR-G MT cells. PBMC pretreatment with IL-2 allowed reaching 65 ± 3% of Cetuximab-mediated ADCC against IIB-BR-G and 63 ± 6.5% against IIB-BR-G MT. Furthermore, IL-15 pretreatment increased the ADCC up to 71 ± 3% in IIB-BR-G and 79 ± 3.5% in IIB-BR-G MT. We suggest that NK cells are the effectors present in PBMC since they were able to induce ADCC at lower effector:target ratios. Besides, IL-2- and mainly IL-15-induced upregulation of NK activating receptors CD16 and NKG2D and enhanced IFN-γ production. EGFR-expressing TNBC could be killed by Cetuximab-mediated ADCC at clinically achievable concentrations. IL-15 could advantageously replace IL-2 in most of its immunologic activities, stimulating the ability to produce IFN-γ, and paralleling the up-regulation of activating receptors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Not only EGFR-specific mAbs (Roberti et al., 2011) but also EGFR-targeting TKIs such as erlotinib (in the presence of a tumor-targeting mAb) (Cavazzoni et al., 2012; Mallmann-Gottschalk et al., 2019) promote ADCC by NK cells, which, in the case of TKIs, originates from the upregulation of the mAb target (e.g., EGFR, HER2) by malignant cells (Cavazzoni et al., 2012; Mallmann-Gottschalk et al., 2019”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Roberti et al., 2011
In the citing paper
“induction of NK-cell-mediated ADCC of cancer cells with mutated KRAS”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Roberti et al., 2011
Citations
Cites
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938 · cited 1×
“using cDNA microarrays [1–3].”
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091 · cited 1×
“TNBC is associated with a more aggressive clinical course and worse clinical outcome than non-TNBC [ 4 ].”
BackgroundCetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 2×
“For instance, activating mutations within K-RAS constitutively activates the RAS-signaling pathway and can predict resistance to anti-EGFR mAbs [8, 9].”
BackgroundLiedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892 · cited 1×
“Although TNBCs are quite sensitive to taxaneand anthracycline-containing regimens in the preoperative setting, they are nevertheless associated with poor long-term outcomes [5].”
BackgroundKRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229 · cited 1×
“In this sense, failure to respond to Cetuximab was associated with mutations in K-RAS that lead to constitutive mitogen-activated protein kinase signaling [35].”
BackgroundEGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,058 · cited 1×
“EGFR regulates cancer cell proliferation, apoptosis, and tumor-induced neoangiogenesis, and has been validated as a relevant therapeutic target in several human cancers [6].”
BackgroundGenes that mediate breast cancer metastasis to the brain
Bos, P. D., Zhang, X. H.-F., Nadal, C., Shu, W., Gomis, R. R., Nguyen, D. X., Minn, A. J., van de Vijver, M. J., Gerald, W. L., Foekens, J. A., et al. (2009) · Nature · doi:10.1038/nature08021 · Cited by 1,863 · cited 1×
“In other studies, EGFR-expressing BCs have been treated with Cetuximab in vitro [30], in mouse models [31] and in patients [32] based on the direct activity of the mAb on the EGFR signaling pathway.”
BackgroundHuman NK Cell Education by Inhibitory Receptors for MHC Class I
Anfossi, N., André, P., Guia, S., Falk, C. S., Roetynck, S., Stewart, C. A., Breso, V., Frassati, C., Reviron, D., Middleton, D., et al. (2006) · Immunity · doi:10.1016/j.immuni.2006.06.013 · Cited by 1,211 · cited 1×
“release of cytotoxic, granzyme-containing granules, and INF-c secretion [17–19].”
BackgroundAllegra, C. J., Jessup, J. M., Somerfield, M. R., Hamilton, S. R., Hammond, E. H., Hayes, D. F., McAllister, P. K., Morton, R. F., & Schilsky, R. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9170 · Cited by 1,156 · cited 1×
“For instance, activating mutations within K-RAS constitutively activates the RAS-signaling pathway and can predict resistance to anti-EGFR mAbs [8, 9].”
BackgroundIn Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer
Pagès, F., Kirilovsky, A., Mlecnik, B., Asslaber, M., Tosolini, M., Bindea, G., Lagorce, C., Wind, P., Marliot, F., Bruneval, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6147 · Cited by 954 · cited 1×
“One of the possibilities is the low proportion of CD3CD56 (NK cells) infiltrating CRC tumors [20] and the low functional capacity of these cells observed in cancer patients [21–23].”
Background
Research works printed but not linked: 2
- Tavassoli F, Deville P (2003) World Health Organization: tumours of the breast and female genital organs (2003) (Who/IARC Classifications of Tumours). IARC, Lyon
- Carson WE, Fehniger TA, Haldar S, Eckhert K, Lindemann MJ, Lai CF, Croce CM, Baumann H, Caligiuri MA (1997) A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest 99:937–943 · DOI · Paper page
Cited by
Cytokines in the Treatment of Cancer
Conlon, K. C., Miljkovic, M. D., & Waldmann, T. A. (2019) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2018.0019 · Cited by 518
Cytokines in Cancer Immunotherapy
Waldmann, T. A. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028472 · Cited by 507
“could be used with anticancer vaccines, cellular therapy, or with tumor-directedmonoclonal antibodies (Sondel and Hank 1997; Moga et al. 2008; Roberti et al. 2011).”
BackgroundJie, H.-B., Schuler, P. J., Lee, S. C., Srivastava, R. M., Argiris, A., Ferrone, S., Whiteside, T. L., & Ferris, R. L. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2788 · Cited by 266
IL-15 in the Combination Immunotherapy of Cancer
Waldmann, T. A., Dubois, S., Miljkovic, M. D., & Conlon, K. C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00868 · Cited by 247
Waldmann, T. A. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0009 · Cited by 238
Metadata
- Authors
- Roberti, M. P., Barrio, M. M., Bravo, A. I., Rocca, Y. S., Arriaga, J. M., Bianchini, M., Mordoh, J., & Levy, E. M.
- Affiliations
- Instituto Alexander Fleming (AR)
- Consejo Nacional de Investigaciones Científicas y Técnicas (AR)
- Corresponding author
- Levy, E. M.
- Venue
- Breast Cancer Research and Treatment
- Published
- 2011-02-10
- Volume
- 130
- Issue
- 2
- Pages
- 465-475
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- OpenAlex
- W2081328283
- Cited by
- 51
- References
- 45
- Citations by year
- 2026: 1 · 2024: 3 · 2022: 2 · 2021: 5 · 2020: 6 · 2019: 4 · 2018: 4 · 2017: 4 · 2015: 6 · 2014: 2 · 2013: 1 · 2012: 8
- FWCI
- 2.27
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (tdm)
- Locations
- Breast Cancer Research and Treatment (publishedVersion)
- PubMed (publishedVersion)
- CONICET Digital (CONICET) (submittedVersion, cc-by-nc-sa)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- triple-negative breast cancer, cetuximab, antibody-dependent cellular cytotoxicity, IL-15, interleukin-2, natural killer cells, EGFR, KRAS mutation, CD16, NKG2D, interferon-gamma, NK cell activating receptors, metastatic breast cancer, cancer immunotherapy, peripheral blood mononuclear cells
- MeSH terms
- Cetuximab, Antibodies, Monoclonal, Antineoplastic Agents, Base Sequence, Breast Neoplasms, DNA Mutational Analysis, Female, Humans, Interferon-gamma, Interleukin-2, Killer Cells, Natural, Proto-Oncogene Proteins, Receptors, Estrogen, Receptors, Progesterone, Up-Regulation, Proto-Oncogene Proteins p21(ras), Apoptosis, Point Mutation, Receptors, IgG, ras Proteins, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Coculture Techniques, Interleukin-15, Cell Line, Tumor, Cell Proliferation, NK Cell Lectin-Like Receptor Subfamily K, GPI-Linked Proteins, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR. https://app.cochat.ai/papers/10.1007/s10549-011-1360-2
- The paper
- Roberti, M. P., Barrio, M. M., Bravo, A. I., Rocca, Y. S., Arriaga, J. M., Bianchini, M., Mordoh, J., & Levy, E. M. (2011). IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-011-1360-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.